Please login to the form below

Not currently logged in
Email:
Password:

KaloBios names Herb Cross as CFO

He joins from Affymax

Herb Cross is to join KaloBios as the company's new chief financial officer.

After a transition period, he will succeed Jeffrey Cooper sometime in October or November, when Cooper is set to retire to spend more time with his family.

Cross joins from biopharma company Affymax, where he was also chief financial officer.

David Pritchard, president and CEO of KaloBios, described Cross as a “well respected finance professional with over sixteen years of experience”.

"His prior work in monoclonal antibody companies and his broad leadership roles in public companies will be invaluable to KaloBios as we focus on our next stage of growth and development,” added Pritchard.

This growth is being led by three drug development programmes for therapies to treat respiratory disorders and cancer.

This includes KB001-A, which is being developed in partnership with Sanofi for the treatment of Pseudomonas aeruginosa (Pa) infections as well as by KalaBios alone as cystic fibrosis treatment.

Cross said: "KaloBios has an interesting and diverse pipeline of monoclonal antibody therapeutic candidates in clinical development, in important areas of unmet medical need.” 

23rd September 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics